Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
59 participants
OBSERVATIONAL
2020-08-01
2024-02-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain Imaging in the Diabetes Prevention Program Outcomes Study
NCT03757910
Imaging of Brain Amyloid Plaques in the Aging Population
NCT00950430
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
NCT01826110
Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment
NCT04505735
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
NCT00407576
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MESA study participants
Current participants in the MESA study in New York City, 60 years or older, fluent in English or Spanish, able to participate in the brain imaging study
11C-PIB
Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
11C-PIB
Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 60 years or older
* Fluent in English and/or Spanish.
* Able to participate in all scheduled evaluations and to complete all required tests and procedures.
Exclusion Criteria
* Any serious medical condition which would prevent long-term participation
* Pregnancy
* Weight \>300 pounds
* Participants previously diagnosed or adjudicated to have dementia
* Participants unwilling to undergo cognitive testing
* Plans to leave the community within five years
* Language barrier (speaks other than English, Spanish, Chinese)
* Inability to give informed consent or to obtain consent from a Legally Authorized Representative (LAR)
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University
OTHER
National Institute on Aging (NIA)
NIH
José A. Luchsinger
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
José A. Luchsinger
Associate Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
José Luchsinger, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Professor of Medicine and Epidemiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Columbia University Irving Medical Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAS2808
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.